The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Potential Role of the Gut Microbiome In Colorectal Cancer Progression
Open accessAbstract
An increasing number of studies have revealed that the progression of colorectal cancer (CRC) is related to gut microbiome composition. Under normal conditions, the gut microbiome acts as a barrier to other pathogens or infections in the intestine and modulates inflammation by affecting the host immune system. These gut microbiota are not only related to the intestinal inflammation associated with tumorigenesis but also modulation of the anti-cancer immune response. Thus, they are associated with tumor progression and anti-cancer treatment efficacy. Studies have shown that the gut microbiota can be used as biomarkers to predict the effect of immunotherapy and improve the efficacy of immunotherapy in treating CRC through modulation. In this review, we discuss the role of the gut microbiome as revealed by recent studies of the growth and progression of CRC along with its synergistic effect with anti-cancer treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Linking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Gut microbiota in human metabolic health and disease
Fan, Y., & Pedersen, O. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0433-9 · Cited by 4,724
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387 · cited 1×
“They play an important role in maintaining a normal physiologic environment, including energy metabolism, interacting with the normal gut barrier system, promoting the survival of epithelial cells, and, importantly, protecting our body against other external or opportunistic pathogens (8).”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“The efficacy of a PD-L1 inhibitor was also shown to be modulated by the gut microbiota composition in a mouse tumor model (103).”
BackgroundDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“difficile infection, IBD, and restored eubiosis (111, 112).”
BackgroundIntroduction to the human gut microbiota
Thursby, E., & Juge, N. (2017) · Biochemical Journal · doi:10.1042/bcj20160510 · Cited by 3,600
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 2×
“The efficacy of CTLA-4 inhibitors was demonstrated to be altered by the population of the gut microbiome (102).”
BackgroundThe human microbiome: at the interface of health and disease
Cho, I., & Blaser, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3182 · Cited by 3,449
Bacterial Community Variation in Human Body Habitats Across Space and Time
Costello, E. K., Lauber, C. L., Hamady, M., Fierer, N., Gordon, J. I., & Knight, R. (2009) · Science · doi:10.1126/science.1177486 · Cited by 3,231 · cited 1×
“In this context, the gut environment, including the microbiome, has been in the spotlight and has emerged as an important factor related to CRC (6).”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
The gut microbiota, bacterial metabolites and colorectal cancer
Louis, P., Hold, G. L., & Flint, H. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3344 · Cited by 2,816
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718 · cited 3×
“are associated with CRC in humans; however, it remains unclear whether this is indirect or causal (38).”
BackgroundInfluentialRubinstein, M. R., Wang, X., Liu, W., Hao, Y., Cai, G., & Han, Y. W. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.012 · Cited by 2,476
Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 1×
“Butyrate, one of the SCFA metabolites produced by probiotics, can induce the expansion of T reg lymphocytes for regulating the immune response in colorectal tissues and suppressing carcinogenesis and tumor growth (92).”
BackgroundCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043
Gut microbiota-derived metabolites as key actors in inflammatory bowel disease
Lavelle, A., & Sokol, H. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0258-z · Cited by 2,015
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 1×
“Although clinical application as a treatment for CRC is still unexplored, a recent FMT study of melanoma patients reported that FMT succeeded in overcoming resistance to immunotherapy in patients who did not respond to immunotherapy (115, 116).”
BackgroundFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
The gut microbiome in health and in disease
Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000139 · Cited by 1,682
Gut microbiome development along the colorectal adenoma-carcinoma sequence
Feng, Q., Liang, S., Jia, H., Stadlmayr, A., Tang, L., Lan, Z., Zhang, D., Xia, H., Xu, X., Jie, Z., et al. (2015) · Nature Communications · doi:10.1038/ncomms7528 · Cited by 1,506 · cited 1×
“It is important to note that most of these environmental factors can induce changes in the gut microbiota (26, 28, 29).”
BackgroundGur, C., Ibrahim, Y., Isaacson, B., Yamin, R., Abed, J., Gamliel, M., Enk, J., Bar-On, Y., Stanietsky-Kaynan, N., Coppenhagen-Glazer, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.010 · Cited by 1,490 · cited 1×
“nucleatum in various carcinomas including CRC (80).”
Yachida, S., Mizutani, S., Shiroma, H., Shiba, S., Nakajima, T., Sakamoto, T., Watanabe, H., Masuda, K., Nishimoto, Y., Kubo, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0458-7 · Cited by 1,429
Oxidative DNA damage and disease: induction, repair and significance
Evans, M. D., Dizdaroglu, M., & Cooke, M. S. (2004) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2003.11.001 · Cited by 1,372 · cited 1×
“faecalis can produce hydroxyl radicals (56, 57), which are potent mutagens that cause DNA breaks, point mutations, and protein-DNA crosslinking, thereby contributing to chromosomal instability and CRC risk (58).”
BackgroundStructural segregation of gut microbiota between colorectal cancer patients and healthy volunteers
Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S., & Zhao, L. (2012) · The ISME Journal · doi:10.1038/ismej.2011.109 · Cited by 1,287 · cited 3×
“A total of 11 operational taxonomic units (OTUs) belonging to the genera Enterococcus , Escherichia/Shigella , Klebsiel la , Streptococcus, and Peptostreptococcus were significantly found to be more abundant in the gut microbiota of CRC patients, while 5 OTUs belonging to Roseburia and other butyrateproducing bacteria…”
BackgroundResultParamsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276 · cited 1×
“difficile infection, IBD, and restored eubiosis (111, 112).”
BackgroundYu, J., Feng, Q., Wong, S. H., Zhang, D., Liang, Q. Y., Qin, Y., Tang, L., Zhao, H., Stenvang, J., Li, Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-309800 · Cited by 1,253
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200 · cited 1×
“Dysbiosis in the intestines is known to be associated with the pathogenesis of a variety of diseases, including neurological, gastrointestinal, and metabolic diseases (12).”
BackgroundFusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., Yang, J., Dou, R., Masugi, Y., Song, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310101 · Cited by 1,080 · cited 1×
“nucleatum is associated with worse prognosis in CRC patients (77, 78).”
BackgroundHuman Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal Cancer
Chen, W., Liu, F., Ling, Z., Tong, X., & Xiang, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039743 · Cited by 1,034
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance
Rosshart, S. P., Vassallo, B. G., Angeletti, D., Hutchinson, D. S., Morgan, A. P., Takeda, K., Hickman, H. D., McCulloch, J. A., Badger, J. H., Ajami, N. J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.016 · Cited by 862
Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells
Cuevas-Ramos, G., Petit, C. R., Marcq, I., Boury, M., Oswald, E., & Nougayrède, J.-P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001261107 · Cited by 855
Quévrain, E., Maubert, M. A., Michon, C., Chain, F., Marquant, R., Tailhades, J., Miquel, S., Carlier, L., Bermúdez-Humarán, L. G., Pigneur, B., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-307649 · Cited by 841
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777 · cited 1×
“It is known that changes in the gut microbiota not only affect tumor immunotherapy, but also affect therapeutic toxicity (22).”
BackgroundInfluence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer
Song, M., Chan, A. T., & Sun, J. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.06.048 · Cited by 752
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · cited 1×
“In addition, FMT can be helpful in alleviating the side effects of ICIs such as immune checkpoint inhibitor-associated colitis (114).”
BackgroundGut mucosal microbiome across stages of colorectal carcinogenesis
Nakatsu, G., Li, X., Zhou, H., Sheng, J., Wong, S. H., Wu, W. K. K., Ng, S. C., Tsoi, H., Dong, Y., Zhang, N., et al. (2015) · Nature Communications · doi:10.1038/ncomms9727 · Cited by 701 · cited 1×
“It is important to note that most of these environmental factors can induce changes in the gut microbiota (26, 28, 29).”
BackgroundFusobacterium nucleatum and T Cells in Colorectal Carcinoma
Mima, K., Sukawa, Y., Nishihara, R., Qian, Z. R., Yamauchi, M., Inamura, K., Kim, S. A., Masuda, A., Nowak, J. A., Nosho, K., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1377 · Cited by 669
Chung, L., Thiele Orberg, E., Geis, A. L., Chan, J. L., Fu, K., DeStefano Shields, C. E., Dejea, C. M., Fathi, P., Chen, J., Finard, B. B., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.01.007 · Cited by 644
The Gut Microbiome Modulates Colon Tumorigenesis
Zackular, J. P., Baxter, N. T., Iverson, K. D., Sadler, W. D., Petrosino, J. F., Chen, G. Y., & Schloss, P. D. (2013) · mBio · doi:10.1128/mbio.00692-13 · Cited by 629
Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients
Rafter, J., Bennett, M., Caderni, G., Clune, Y., Hughes, R., Karlsson, P. C., Klinder, A., O'Riordan, M., O'Sullivan, G. C., Pool-Zobel, B., et al. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.2.488 · Cited by 589
The Intestinal Microbiota and Colorectal Cancer
Cheng, Y., Ling, Z., & Li, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615056 · Cited by 582
Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity
Long, X., Wong, C. C., Tong, L., Chu, E. S. H., Ho Szeto, C., Go, M. Y. Y., Coker, O. O., Chan, A. W. H., Chan, F. K. L., Sung, J. J. Y., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0541-3 · Cited by 557 · cited 2×
“anaerobius, putative cell wall binding repeat 2 (PCWBR2), promotes CRC development in APC mice (63).”
BackgroundInflammation and colorectal cancer: colitis-associated neoplasia
Grivennikov, S. I. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0352-6 · Cited by 551
Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer
Coker, O. O., Nakatsu, G., Dai, R. Z., Wu, W. K. K., Wong, S. H., Ng, S. C., Chan, F. K. L., Sung, J. J. Y., & Yu, J. (2019) · Gut · doi:10.1136/gutjnl-2018-317178 · Cited by 511
Flanagan, L., Schmid, J., Ebert, M., Soucek, P., Kunicka, T., Liska, V., Bruha, J., Neary, P., Dezeeuw, N., Tommasino, M., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2081-3 · Cited by 498
Cougnoux, A., Dalmasso, G., Martinez, R., Buc, E., Delmas, J., Gibold, L., Sauvanet, P., Darcha, C., Déchelotte, P., Bonnet, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305257 · Cited by 486
Colonization of the Human Gut by E. coli and Colorectal Cancer Risk
Bonnet, M., Buc, E., Sauvanet, P., Darcha, C., Dubois, D., Pereira, B., Déchelotte, P., Bonnet, R., Pezet, D., & Darfeuille-Michaud, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1343 · Cited by 475 · cited 1×
“coli is increased in CRC tumor tissues compared with in normal colon tissues (82).”
BackgroundTsoi, H., Chu, E. S. H., Zhang, X., Sheng, J., Nakatsu, G., Ng, S. C., Chan, A. W. H., Chan, F. K. L., Sung, J. J. Y., & Yu, J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.009 · Cited by 438
Touchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., Le Vacon, F., & de La Cochetière, M. F. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12878 · Cited by 425
Gradel, K. O., Nielsen, H. L., Schønheyder, H. C., Ejlertsen, T., Kristensen, B., & Nielsen, H. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.001 · Cited by 424
Enterotoxigenic Bacteroides fragilis: a Rogue among Symbiotes
Sears, C. L. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00053-08 · Cited by 411
He, Z., Gharaibeh, R. Z., Newsome, R. C., Pope, J. L., Dougherty, M. W., Tomkovich, S., Pons, B., Mirey, G., Vignard, J., Hendrixson, D. R., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317200 · Cited by 409 · cited 2×
“Campylobacter jejuni produces a cytolethal distending toxin (CDT), a genetic toxin with DNAse activity that causes DNA double-strand breaks and promotes colorectal tumorigenesis (70).”
BackgroundArthur, J. C., Gharaibeh, R. Z., Mühlbauer, M., Perez-Chanona, E., Uronis, J. M., McCafferty, J., Fodor, A. A., & Jobin, C. (2014) · Nature Communications · doi:10.1038/ncomms5724 · Cited by 392
Boleij, A., van Gelder, M. M. H. J., Swinkels, D. W., & Tjalsma, H. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir609 · Cited by 377
Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis
Sears, C. L., Geis, A. L., & Housseau, F. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72334 · Cited by 353
Advancing functional and translational microbiome research using meta-omics approaches
Zhang, X., Li, L., Butcher, J., Stintzi, A., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 340
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response
Sánchez-Alcoholado, L., Ramos-Molina, B., Otero, A., Laborda-Illanes, A., Ordóñez, R., Medina, J. A., Gómez-Millán, J., & Queipo-Ortuño, M. I. (2020) · Cancers · doi:10.3390/cancers12061406 · Cited by 337
Fecal microbiota transplantation: past, present and future
Aroniadis, O. C., & Brandt, L. J. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a4b3e · Cited by 336 · cited 1×
“Fecal microbiota transplantation (FMT) is an emerging biotherapeutic method for altering the microbiota by transplanting stool information from healthy donors to patients (110).”
MethodLifestyle and dietary environmental factors in colorectal cancer susceptibility
Murphy, N., Moreno, V., Hughes, D. J., Vodicka, L., Vodicka, P., Aglago, E. K., Gunter, M. J., & Jenab, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.06.005 · Cited by 311
The Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Schloss, P. D. (2018) · mBio · doi:10.1128/mbio.00525-18 · Cited by 280
Microbiome, Inflammation, and Cancer
Francescone, R., Hou, V., & Grivennikov, S. I. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000048 · Cited by 266
Viljoen, K. S., Dakshinamurthy, A., Goldberg, P., & Blackburn, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119462 · Cited by 256 · cited 1×
“Moreover, early-stage CRC patients (advanced adenoma) have a different microbiome composition compared to advanced-stage CRC patients (definitive CRC) (35, 39).”
ResultThe Relationship Between Gut Microbiota and Inflammatory Diseases: The Role of Macrophages
Wang, J., Chen, W.-D., & Wang, Y.-D. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01065 · Cited by 253
Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics
García-González, A. P., Ritter, A. D., Shrestha, S., Andersen, E. C., Yilmaz, L. S., & Walhout, A. J. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.046 · Cited by 243
Wang, X., & Huycke, M. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.040 · Cited by 242
Biarc, J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh091 · Cited by 241
Abdulamir, A. S., Hafidh, R. R., & Bakar, F. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-249 · Cited by 240
Moving from probiotics to precision probiotics
Veiga, P., Suez, J., Derrien, M., & Elinav, E. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0721-1 · Cited by 235
Gamallat, Y., Meyiah, A., Kuugbee, E. D., Hago, A. M., Chiwala, G., Awadasseid, A., Bamba, D., Zhang, X., Shang, X., Luo, F., et al. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.07.001 · Cited by 232
Nam, Y.-D., Kim, H. J., Seo, J.-G., Kang, S. W., & Bae, J.-W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082659 · Cited by 230
Wei, Z., Cao, S., Liu, S., Yao, Z., Sun, T., Li, Y., Li, J., Zhang, D., & Zhou, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10064 · Cited by 222
Huycke, M. M., Moore, D., Joyce, W., Wise, P., Shepard, L., Kotake, Y., & Gilmore, M. S. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02638.x · Cited by 209
Yuan, L., Zhang, S., Li, H., Yang, F., Mushtaq, N., Ullah, S., Shi, Y., An, C., & Xu, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.165 · Cited by 208
Lu, R., Wu, S., Zhang, Y.-G., Xia, Y., Liu, X., Zheng, Y., Chen, H., Schaefer, K. L., Zhou, Z., Bissonnette, M., et al. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.20 · Cited by 206
Wang, X., Allen, T. D., May, R. J., Lightfoot, S., Houchen, C. W., & Huycke, M. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1551 · Cited by 205
Allen, J., & Sears, C. L. (2019) · Genome Medicine · doi:10.1186/s13073-019-0621-2 · Cited by 204
Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats.
Reddy, B. S., Narisawa, T., Wright, P., Vukusich, D., Weisburger, J. H., & Wynder, E. L. (1975) · PubMed · Cited by 193
Role of diet and gut microbiota on colorectal cancer immunomodulation
Almeida, C. V. D., de Camargo, M. R., Russo, E., & Amedei, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i2.151 · Cited by 178
Lactate has the potential to promote hydrogen sulphide formation in the human colon
Marquet, P., Duncan, S. H., Chassard, C., Bernalier-Donadille, A., & Flint, H. J. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2009.01750.x · Cited by 164
Saffarian, A., Mulet, C., Regnault, B., Amiot, A., Tran-Van-Nhieu, J., Ravel, J., Sobhani, I., Sansonetti, P. J., & Pédron, T. (2019) · mBio · doi:10.1128/mbio.01315-19 · Cited by 164
Ye, X., Wang, R., Bhattacharya, R., Boulbes, D. R., Fan, F., Xia, L., Adoni, H., Ajami, N. J., Wong, M. C., Smith, D. P., et al. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0178 · Cited by 163
Lü, L., Li, X., Zhong, W., Yang, M., Xu, M., Sun, Y., Ma, J., Liu, T., Song, X., Dong, W., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.021 · Cited by 160
Exploring the Role of Gut Microbiome in Colon Cancer
Chattopadhyay, I., Dhar, R., Pethusamy, K., Seethy, A. A., Srivastava, T. P., Sah, R., Sharma, J. N., & Karmakar, S. (2021) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-021-03498-9 · Cited by 156
Hayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145
Streptococcus bovis endocarditis, a silent sign for colonic tumour
Gupta, A., Madani, R., & Mukhtar, H. (2009) · Colorectal Disease · doi:10.1111/j.1463-1318.2009.01814.x · Cited by 143
Figliuolo, V. R., dos Santos, L. M., Abalo, A., Nanini, H. F., Santos, A. B. G., Brittes, N. M., Bernardazzi, C., de Souza, H. S. P., Vieira, L. Q., Coutinho‐Silva, R., et al. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.09.014 · Cited by 137
Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer
Zheng, X., Hur, J., Nguyen, L. H., Liu, J., Song, M., Wu, K., Smith-Warner, S. A., Ogino, S., Willett, W. C., Chan, A. T., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa164 · Cited by 136
Metabolite and Microbiome Interplay in Cancer Immunotherapy
Johnson, C. H., Spilker, M. E., Goetz, L. H., Peterson, S. N., & Siuzdak, G. E. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0309 · Cited by 113
Huycke, M. M., & Moore, D. R. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00977-2 · Cited by 109
Rodríguez-Arrastia, M. J., Martinez‐Ortigosa, A., Rueda‐Ruzafa, L., Ayora, A. F., & Ropero‐Padilla, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084265 · Cited by 104
Salmonella protein AvrA activates the STAT3 signaling pathway in colon cancer
Lu, R., Wu, S., Zhang, Y.-G., Xia, Y., Zhou, Z., Kato, I., Dong, H., Bissonnette, M., & Sun, J. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.001 · Cited by 99
Busnelli, M., Manzini, S., & Chiesa, G. (2019) · Nutrients · doi:10.3390/nu12010079 · Cited by 98
Deng, Z., Mu, J., Tseng, M. T., Wattenberg, B. W., Zhuang, X., Egilmez, N. K., Wang, Q., Zhang, L., Norris, J. S., Guo, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7956 · Cited by 96
Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis
Al-Qadami, G. H., Sebille, Y. Z. A. V., Le, H. V., & Bowen, J. M. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1595586 · Cited by 94
Campylobacter jejuni Induces Colitis Through Activation of Mammalian Target of Rapamycin Signaling
Sun, X., Threadgill, D., & Jobin, C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.042 · Cited by 84
Inhibition of Chronic Ulcerative Colitis-associated Adenocarcinoma Development in Mice by VSL#3
Talero, E., Bolívar, S., Ávila‐Román, J., Alcaide, A. M., Fiorucci, S., & Motilva, V. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000346 · Cited by 73
Lee, H. A., Kim, H., Lee, K., & Park, K.-Y. (2015) · Journal of Medicinal Food · doi:10.1089/jmf.2015.3577 · Cited by 70
Self-citationVéziant, J., Gagnière, J., Jouberton, E., Bonnin, V., Sauvanet, P., Pezet, D., Barnich, N., Miot‐Noirault, E., & Bonnet, M. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i3.293 · Cited by 70
Relationship between intestinal microbiota and colorectal cancer
Çıpe, G., İdiz, U. O., Fırat, Y. D., & Bektaşoğlu, H. K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i10.233 · Cited by 69
Son, J. S., Khair, S., Pettet, D. W., Ouyang, N., Tian, X., Zhang, Y., Zhu, W., Mackenzie, G. G., Robertson, C. E., Ir, D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127985 · Cited by 61
Novel Regulatory Roles of Wnt1 in Infection-Associated Colorectal Cancer
Wang, J., Lu, R., Fu, X., Dan, Z., Zhang, Y., Chang, X., Liu, Q., Xia, Y., Liu, X., & Sun, J. (2018) · Neoplasia · doi:10.1016/j.neo.2018.03.001 · Cited by 46
Martin, O. C. B., Bergonzini, A., D’Amico, F., Chen, P., Shay, J. W., Dupuy, J., Svensson, M., Masucci, M. G., & Frisan, T. (2019) · Cellular Microbiology · doi:10.1111/cmi.13099 · Cited by 46
Winters, M. D., Tl, S., Joyce, W., Glore, S. R., & Huycke, M. M. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00710.x · Cited by 44
Metadata
- Authors
- Kim, J., & Lee, H. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-07
- Volume
- 12
- Pages
- 807648-807648
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4205468205
- Cited by
- 259
- References
- 113
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.